<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368520</url>
  </required_header>
  <id_info>
    <org_study_id>COLDstudy</org_study_id>
    <nct_id>NCT04368520</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Optimise Levels of Vitamin D for Rhinovirus Protection</brief_title>
  <official_title>Clinical Trial to Optimise Levels of Vitamin D for Rhinovirus Protection (COLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II randomised, placebo-controlled trial to identify the optimal regimen of vitamin D&#xD;
      supplementation for rhinovirus protection, determined by host responses to a clinically&#xD;
      induced rhinovirus challenge. The primary outcome is rhinovirus titre after inoculation with&#xD;
      rhinovirus; secondary outcomes are self-reported respiratory symptom scores, concentrations&#xD;
      of cytokines and chemokines sampled from the nasal mucosa, and the transcriptional responses&#xD;
      of nasal epithelial cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two treatment arms of vitamin D3: low dose (800IU) vs. high dose (3,200IU) given daily, for 3 months</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rhinovirus titres</measure>
    <time_frame>+3 to +5 days after inoculation</time_frame>
    <description>PCR-detected rhinovirus-16 load sampled from the nasal mucosa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory symptom score (Jackson Score)</measure>
    <time_frame>+1 to +14 days after inoculation</time_frame>
    <description>Total self-reported respiratory symptom score (scored 0-32; increasing score equals increasing symptom severity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine and chemokine concentrations</measure>
    <time_frame>Day 0 and +4 days after inoculation</time_frame>
    <description>Change in concentrations of inflammatory mediators (Including, but not limited to IL-1β, IL-2, IL-4, IL-5, Il-6, IL- 7, IL-8 [CXCL8], IL-10, IL-12, IL-13, IL-15, IL-17, IL-1RA, IL-2R, IFN-α, IFN-γ, TNF-α, MCP-1 [CCL2], MIP- 1α [CCL3], MIP-1β [CCL4], RANTES [CCL5], eotaxin [CCL11], MIG [CXCL9], IP-10 [CXCL10], EGF, FGF-basic, HGF, VEGF, G-CSF, GM-CSF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of vitamin D-regulated gene expression</measure>
    <time_frame>Day 0 and +4 days after inoculation</time_frame>
    <description>Change in expression of DHCR7, CYP2R1, CYP3A4, CYP27A1, CYP27B1, CYP24A1, VDR, DBP, RXRA</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>800 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months</description>
    <arm_group_label>Low dose vitamin D3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>3,200 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months</description>
    <arm_group_label>High dose vitamin D3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Hypromellose capsules, given daily for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-70 years&#xD;
&#xD;
          2. Gives written informed consent&#xD;
&#xD;
          3. Serum 25-hydroxyvitamin D concentration &lt;75 nmol/L&#xD;
&#xD;
          4. Agrees not to take supplement containing vitamin D during participation&#xD;
&#xD;
          5. Agrees not to commence smoking or vaping during participation&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Current smoker or vaper&#xD;
&#xD;
          2. Taken vitamin D supplement or other supplement containing vitamin D, in previous 3&#xD;
             months&#xD;
&#xD;
          3. Sunny holiday abroadI, defined as any location 51 degrees North/South of the equator,&#xD;
             for ≥1 week, in the previous 3 months&#xD;
&#xD;
          4. Dependent(s) &lt;6 months old&#xD;
&#xD;
          5. Positive serology for anti-RV16 antibodies&#xD;
&#xD;
          6. Living with someone with severe airways disease&#xD;
&#xD;
          7. Any of the following medical conditions:&#xD;
&#xD;
               1. Diabetes mellitus&#xD;
&#xD;
               2. Asthma&#xD;
&#xD;
               3. Chronic Obstructive Pulmonary Disease&#xD;
&#xD;
               4. Respiratory allergies&#xD;
&#xD;
               5. Sarcoidosis&#xD;
&#xD;
               6. Hyperparathyroidism&#xD;
&#xD;
               7. Nephrolithiasis&#xD;
&#xD;
               8. Active tuberculosis&#xD;
&#xD;
               9. Liver failure&#xD;
&#xD;
              10. Renal failure&#xD;
&#xD;
              11. Lymphoma or other malignancy not in remission for ≥ 3 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David A Jolliffe, PhD</last_name>
    <phone>07920648370</phone>
    <email>d.a.jolliffe@qmul.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adrian R Martineau, PhD</last_name>
    <phone>0207 882 2551</phone>
    <email>a.martineau@qmul.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Sebastian L Johnston, PhD</last_name>
      <phone>020 7594 3764</phone>
      <email>s.johnston@imperial.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhinovirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified IPD will be shared with other researchers subject to terms of Data Transfer Agreement and IRB approval</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>2 years after completion of the trial</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

